have supported discontinuing RSB 1-2 years after transplant in standard risk patients. 3, 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] In pediatric studies, late rejection is an important finding as it has been associated with decreased graft survival. 24, 25 The rate of rejection found by RSB in the second year and beyond post-HT is significantly more variable, ranging anywhere from 0% to 12%. 7, 8, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] These previous studies (from before 2000) may not reflect current practices and risk and generally did not assess the possible time-related risk of late rejection. Due to the conflicting historical data and the absence of contemporary studies in pediatric heart recipients, the practice of long-term RSB in pediatric HT remains controversial.
The primary aims of this study were (a) to characterize the observed rate of positive routine surveillance endomyocardial biopsy in order to assess long-term surveillance protocol performance (beyond 2 years post-HT) and (b) to determine risk factors associated with surveillance-detected rejection.
| ME THODS

| Study population
The inception cohort for this study included HT patients from a pediatric heart transplant center with demographic and post-transplant biopsy history available from institutional electronic health records from January 1995 through July 2015. In order to assess the relationship of early rejection to later rejection risk, we excluded patients with no recorded biopsy results within their first 60 days of transplant. Given our specific aims, we excluded patients who did not have at least 2 full years of post-HT biopsy data. We also excluded retransplant recipients. Further details regarding transplant outcomes in this cohort have been previously reported. 36 The study was approved by the Institutional Review Board.
| Induction and maintenance immunosuppression
Standard protocol consisted of induction with methylprednisolone intraoperatively and either daclizumab, basiliximab, or rabbit antithymoglobulin. Postoperatively, patients received maintenance immunosuppressive therapy consisting of a calcineurin inhibitor (cyclosporine or tacrolimus), mycophenolate mofetil, and methylprednisolone or prednisone, which was tapered over the first post-transplant year. Cyclosporine and tacrolimus dosing were modulated to achieve target troughs of 300-350 or 10-12 g/dL, respectively, for the first three post-transplant months, after which doses were adjusted downward sequentially to maintenance goal troughs of 175-225 g/dL for cyclosporine or 5-7 g/dL for tacrolimus at >24 months post-transplant. Select patients were transitioned to sirolimus at various time points at least 6 months post-transplant and were dosed to achieve a target trough of 6-8 g/dL and continued on reduced-dose cyclosporine or tacrolimus adjusted to achieve target troughs of 100-150 or 2-4 g/dL, respectively.
| Outcome
Biopsies were classified according to the ISHLT 1990 criteria, 37 a standardized grading system to diagnose acute cellular rejection developed by the ISHLT. We considered grades 0 and 1A as "negative for rejection" and 1B and 2 as "mild rejection." Grades 3A, 3B, and 4 (equivalent to 2R-3R rejection using the revised 2004 grading scheme 38 ) were classified as "clinically significant rejection."
Per institutional protocol, after 2 years post-transplant, surveillance biopsies have been routinely performed every 6 months during the study period irrespective of age. However, biopsies were often performed more frequently than every 6 months in patients perceived to be at higher risk for rejection or require heightened surveillance. For example, earlier or more frequent biopsies were performed in patients to follow up a rejection episode, with history of recurrent rejection, with other clinical concern for rejection, after significant changes in immunosuppression, with non-adherence and at the discretion of the team. It was not always clearly defined whether the more frequent biopsies were performed for regular, heightened surveillance, to follow up a rejection episode, or for active concern for new rejection. Thus, all biopsies performed earlier than the protocol guidelines were considered "non-routine." In order to focus the analysis on only routine, standard risk biopsies and assess the performance of an ongoing biannual RSB schedule, only biopsies occurring at least 4.5 months (135 days) after the previous biopsy were considered RSB.
| Statistical analysis
We presented baseline demographics at the time of HT, as well as early rejection history (years 0-2 post-HT), by highest achieved 1990
ISHLT grade category during follow-up (beyond Year 2). Categorical variables were summarized as counts and percentages, and continuous variables were summarized as median with first and third quartiles (Q1,3). Age at transplant and transplant era were categorized based on previously used thresholds.
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To characterize the rate of positive RSB in our time trend analysis, we first calculated and graphed the percentage of clinically significant rejections among total RSB performed from Year 2 to Year 10 post-transplant, overall and also stratified by age-group at HT.
We then fit a multivariable logistic regression model to relate the log to select the best functional form for modeling time. We estimated Huber-White standard errors to account for within-subject correlation and used them to construct 95% CIs for estimated ORs.
To determine risk factors associated with surveillance-detected rejection, we estimated Kaplan-Meier freedom from rejection rates by patient characteristics and used the log-rank test to assess differences in survival probabilities. We then used exhaustive search Table 1 .
The overall empirical rate of rejection detected by RSB after 2 years was 2.9 per 100 patient-years. The percentage of rejections among RSB was 2.6% and remained relatively stable over time ( Figure 2A ). Follow-up rejection patterns differed by age at HT ( Figure 2B ). In all children aged 2 or less at HT, there was a single rejection episode, which occurred in the third year post-HT. Four total rejection episodes were detected in the cohort between ages 2 and 13 at HT. In patients over age 13 at HT, the annual rate of rejection by RSB was higher, ranging from 0 to 15% over time.
After fitting a Cox proportional hazards model with adjustment for transplant era, age at transplant, gender, CHD diagnosis, and history of rejection, time since HT remained unassociated with rejection by RSB (OR = 0.98; 95% CI 0.78-1.23; P = 0.86, Table 2 ). The same model showed that patients over age 13 years at HT were significantly more likely to have rejection diagnosed by RSB compared with patients aged 2 years or less (P = 0.03).
F I G U R E 1 CONSORT diagram of pediatric heart transplant study population Kaplan-Meier curves depicting time to first grade ≥3A rejection by levels of patient characteristics are shown in Figure 3 . Log-rank analysis identified age category at HT and CHD diagnosis as factors univariately associated with time to first occurrence of clinically significant rejection by RSB. Exhaustive search over all patient characteristics in Table 1 yielded the same two factors, and age category at HT was the only one that remained significantly associated with risk of rejection under multivariable Cox analysis (P = 0.008, Table 3 ).
| D ISCUSS I ON
This study demonstrates that most pediatric patients transplanted at our center between 1995 and 2015 did not have significant rejection detected by RSB beyond 2 years after HT. The overall rate of rejection detected by RSB after 2 years was 2.9 per 100 patient-years. Older age at HT was the only factor associated with increased rejection detected by RSB on multivariable analysis. The rate of rejection by RSB did not change across transplant eras or decrease over time after transplant (within 10 years) in the study cohort.
A recent PHTS analysis showed that RSB detected 81.6% of the reported rejection episodes. 26 However, since the PHTS does not collect the number of biopsies performed, the report could not provide the yield of RSB or address how frequently RSB should be performed. This updated pediatric study, which includes data and practices from the earliest era to the current, is the first to specifically investigate the utility and yield of a typical long-term surveillance biopsy protocol and identify factors associated with cellular rejection detected by RSB. Additionally, this time-related analysis is unique in that it utilized fractional polynomial methodology to determine the most appropriate functional form for modeling time, which allowed us to avoid assuming any particular trajectory, linear or otherwise for rejection over time.
There have not been any contemporary pediatric studies of RSB performance using data after 2000. Consistent with earlier studies, our analysis confirms that RSB is exceedingly low yield in patients TA B L E 1 Baseline characteristics of N = 140 patients by highest rejection grade identified beyond 2 y post-HT transplanted as infants. 32, 33 There was only a single episode of rejection by RSB detected in patients ≤2 years old at the time of HT, occurring during the third year post-HT. In children transplanted between 2 and 13 years of age, the rate of rejection detected by RSB was also exceedingly low. On the other hand, late rejection detected by RSB was higher in patients >13 years old at HT. This finding is consistent with previous PHTS studies that have demonstrated older age to be a risk factor for both late rejection and rejection with severe hemodynamic compromise. 8, 24 In older patients, we hypothesize that differences in immunology, non-adherence and psychosocial stressors, donor-related factors, and other unknown influences may potentially contribute to the higher persistent risk of rejection, even late post-HT.
In combination with prior reports, the current study shows that long-term (beyond 2 years post-HT) RSB for asymptomatic acute cellular rejection is low yield and suggests that RSB is not clearly indicated in younger children, especially those aged 2 years or less at HT. In older patients, our data suggest that shown that earlier era, previous rejection, and non-white race were associated with a higher risk of rejection. 24, 25 These factors were not associated with risk for rejection in this single-center analysis, which focused only on RSB and intentionally omitted patients at higher perceived risk who received more frequent biopsies. Rejection episodes detected by clinically indicated biopsies (performed more frequently than standard protocol) were not included in the analysis. Not unexpectedly, the number of early rejection episodes (within 2 years post-HT) in our cohort is lower than what has been previously described. 8 If early rejecters were placed back on standard surveillance protocol, presumably due to clinical stability, they were not at higher risk for a positive RSB in our data.
Unexpectedly, there was a trend toward lower rate of rejection in patients with CHD. This borderline association most likely reflects the fact that the CHD patients were younger at the time of HT (median age 7.5 years vs 11.4 years) and younger age at HT is associated with decreased rejection. The association of CHD with rejection risk was no longer significant in multivariable analysis that included age.
In this analysis, more than half of the biopsies were obtained more frequently than required by the protocol. At our center, patients often received additional biopsies for immunosuppression changes, rejection follow-up, history of recurrent rejection, noncompliance, and, of course, clinical concern for rejection. We intentionally excluded these biopsies to specifically analyze the routine, standard risk biopsies.
| Limitations
There with RSB. The true rejection rates with RSB may be even lower than described. We acknowledge that these data may not include some biopsies performed in the highest risk patients, who were likely biopsied more frequently than every half year. This study intentionally focused on the utility of long-term RSB in otherwise standard risk patients and did not attempt to address the issue of what should be done in patients deemed to be at higher risk for rejection.
We recognize that patients often undergo biopsy for cellular rejection as part of their regular follow-up cardiac catheterization that also includes screening for AMR, evaluating for cardiac allograft vasculopathy and assessing hemodynamics. We elected to not include AMR in our analysis since much of our data predates standard AMR pathologic classifications. However, we have recently reported our center's recent AMR outcomes which demonstrated an exceedingly low incidence of ≥pAMR 2 biopsies.
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Especially for patients in whom long-term routine biopsy is likely low yield, noninvasive methods of surveillance for vasculopathy and graft function deserve further study and consideration. 41 
| CON CLUS IONS
Most pediatric patients do not have significant rejection detected by RSB beyond 2 years after heart transplant. Indiscriminate long-term RSB in pediatric heart transplant should be reexamined
given the low rate of detected rejection. Age at transplant may be an important consideration when determining patient-specific long-term surveillance plans. Prospective evaluation of different long-term surveillance strategies may be warranted.
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